Fulcrum Therapeutics (United States)

company in Cambridge, United States

FULC Nasdaq SEC CIK 1680581
Follow Fulcrum Therapeutics (United States) Weekly email: filings, results

Financials

Reported figures only · latest: Q3 2026 USD · US GAAP
Net income −$10.9M +44.2% vs same quarter last year
EPS, diluted −$0.14 +54.8% vs same quarter last year
Operating cash flow −$13.4M +5.7% vs same quarter last year
Operating income −$13.9M +36.6% vs same quarter last year
Revenue by quarter
$0
$0
$0
$0
Q4 24 Q2 25 Q3 25 Q4 25

Source: SEC XBRL filings · latest filing

The long view

Fiscal years as reported · SEC XBRL filings, US GAAP
Revenue and net income9 fiscal years
  • Revenue
  • Net income
−$150M−$100M−$50M$0$50M$100MFY17FY18FY19FY20FY21FY22FY23FY24FY25
Show the numbers
YearRevenueNet income
FY25$0−$74.9M
FY24$80M−$9.7M
FY23$2.8M−$97.3M
FY22$6.3M−$109.9M
FY21$19.2M−$80.8M
FY20$8.8M−$70.8M
FY19-−$82.7M
FY18-−$32.6M
FY17--
MarginsShare of revenue
  • Operating margin
  • Net margin
−4000%−3000%−2000%−1000%0%FY17FY18FY19FY20FY21FY22FY23FY24FY25
Show the numbers
YearOperating marginNet margin
FY25--
FY24−27.4%−12.2%
FY23−3945.2%−3470.2%
FY22−1774.9%−1732.4%
FY21−423%−421.9%
FY20−811.6%−802.7%
FY19--
FY18--
FY17--
Free cash flowOperating cash flow minus capital expenditure
−$100M−$75M−$50M−$25M$0FY17FY18FY19FY20FY21FY22FY23FY24FY25
Show the numbers
YearFree cash flow
FY25−$60.4M
FY24−$2.5M
FY23−$91.5M
FY22−$99M
FY21−$80.2M
FY20−$55M
FY19−$40.3M
FY18−$31.5M
FY17-
Net margin vs the sectorMedian of Healthcare companies filing with the SEC
  • Fulcrum Therapeutics (United States)
  • Healthcare median
−4000%−3000%−2000%−1000%0%FY17FY18FY19FY20FY21FY22FY23FY24FY25
Show the numbers
YearFulcrum Therapeutics (United States)Healthcare median
FY25-−30.6%
FY24−12.2%−47%
FY23−3470.2%−58%
FY22−1732.4%−80.4%
FY21−421.9%−71.8%
FY20−802.7%−62.2%
FY19-−46.2%
FY18-−49.6%
FY17-−45.9%